InvestorsHub Logo
Followers 52
Posts 5322
Boards Moderated 0
Alias Born 09/16/2013

Re: None

Friday, 05/10/2024 6:25:42 PM

Friday, May 10, 2024 6:25:42 PM

Post# of 699045

MAA Application. As previously reported, the Company filed a Marketing Authorization Application (MAA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) on December 20, 2023, seeking regulatory approval for commercialization of DCVax - L for newly diagnosed and recurrent Glioblastoma (GBM). On January 24, 2024 the Company received notification from the MHRA that the MAA had passed validation. On March 7, 2024, the Company received notification from the MHRA that the validation was confirmed. The Company did not make any amendment or addition to its MAA after the original December 20, 2023 submission.



https://www.sec.gov/ix?doc=/Archives/edgar/data/0001072379/000141057824000741/nwbo-20240331x10q.htm

Anyone who can make you believe absurdities can make you commit atrocities-- Voltaire

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News